Want to see GANX full AI Analyst Report?
Gain Therapeutics (GANX) Stock Statistics & Valuation Metrics
Total Valuation
Gain Therapeutics has a market cap or net worth of $50.19M. The enterprise value is $74.57M.
- Market Cap
- $50.19M
- Enterprise Value
- $74.57M
Share Statistics
Gain Therapeutics has 43,643,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 43,643,620
- Owned by Insiders
- 2.23%
- Owned by Institutions
- 4.33%
Financial Efficiency
Gain Therapeutics’s return on equity (ROE) is -1.09 and return on invested capital (ROIC) is -95.04%.
- Return on Equity (ROE)
- -1.09
- Return on Assets (ROA)
- -0.88
- Return on Invested Capital (ROIC)
- -95.04%
- Return on Capital Employed (ROCE)
- -0.96
- Revenue Per Employee
- 0
- Profits Per Employee
- -960.05K
- Employee Count
- 21
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Gain Therapeutics is -1.92. Gain Therapeutics’s PEG ratio is -0.07.
- PE Ratio
- -1.92
- PS Ratio
- 0.00
- PB Ratio
- 3.65
- Price to FCF
- -2.16
- Price to Operating Cash Flow
- -2.17
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, Gain Therapeutics had revenue of 0 and earned -20.16M in profits. Earnings per share was -0.61.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -18.71M
- Pretax Income
- -19.30M
- Net Income
- -20.16M
- EBITDA
- -19.21M
- Earnings Per Share (EPS)
- -0.61
Cash Flow
In the last 12 months, operating cash flow was -18.95M and capital expenditures -5, giving a free cash flow of -18.95M billion.
- Operating Cash Flow
- -18.95M
- Free Cash Flow
- -18.95M
- Free Cash Flow per Share
- -0.44
Dividends & Yields
Gain Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -46.61%
- Earnings Yield
- -49.19%
Stock Price Statistics
- Beta
- 1.68
- 52-Week Price Change
- -33.13%
- 50-Day Moving Average
- 1.58
- 200-Day Moving Average
- 1.85
- Relative Strength Index (RSI)
- 27.91
- Average Volume (3m)
- 499.84K
Important Dates
Gain Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Gain Therapeutics as a current ratio of 6.63, with Debt / Equity ratio of 3.94%
- Current Ratio
- 6.63
- Quick Ratio
- 6.63
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.05
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Gain Therapeutics has paid 861.12K in taxes.
- Income Tax
- 861.12K
- Effective Tax Rate
- -0.04
Enterprise Valuation
Gain Therapeutics EV to EBITDA ratio is -1.48, with an EV/FCF ratio of -1.49.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.48
- EV to Free Cash Flow
- -1.49
- EV to Operating Cash Flow
- -1.49
Balance Sheet
Gain Therapeutics has $13.08M in cash and marketable securities with $609.87K in debt, giving a net cash position of $12.47M billion.
- Cash & Marketable Securities
- $13.08M
- Total Debt
- $609.87K
- Net Cash
- $12.47M
- Net Cash Per Share
- $0.29
- Tangible Book Value Per Share
- $0.26
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Gain Therapeutics is $7.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $7.20
- Price Target Upside
- 548.65% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 23.02%
Scores
- Smart Score
- 5
- AI Score
- 45
